AAIPharma Charleston Sterile Manufacturing Receives MHRA Approval

AAIPharma's sterile manufacturing plant in Charleston, SC USA received approval from the Medicines and Healthcare products Regulatory Agency (MHRA) to produce aseptic and lyophilized products. The MHRA approval certifies the plant to produce these products for shipment to countries in the European Union (EU) and comes on the heels of a $1,500,000 renovation of the plant. Along with prior approvals from the US Food and Drug Administration (FDA), this approval positions the plant to deliver aseptic contract manufacturing services to clients wishing to supply both commercial and clinical sterile drug products throughout the US and Europe.

"This investment and subsequent MHRA approval of our Charleston plant is very much in line with AAIPharma's goal to deliver high quality pharmaceutical services to meet the needs of the pharmaceutical and biotechnology industries," stated Lee Karras, Sr. Vice President of Global Pharmaceutical Services at AAIPharma.

About AAIPharma Inc.
AAIPharma Inc. is an international pharmaceutical services provider of product development and support services to the pharmaceutical, biotechnology, and medical device industries. AAIPharma's service offerings include: analytical services, product development services, drug delivery technologies, contract manufacturing (solids and parenterals), clinical services (Phase I-IV), clinical packaging and distribution and bioanalytical services.

SOURCE: <%=company1%>